Latest Conference Articles

October 5th 2019, 11:31pm

Lynn Sage Breast Cancer Symposium

Monica Morrow, MD, discusses the factors that impact the decision to use nipple sparing mastectomy versus conventional mastectomy in patients with breast cancer. The decision to use a nipple sparing approach in patients is dependent on 2 considerations. These relate to the cancer as well as cosmetic appearance of the breast.

October 5th 2019, 11:04pm

Lynn Sage Breast Cancer Symposium

Naoto Tada Ueno, MD, PhD, FACP, discusses the diagnosis and treatment of patients with inflammatory breast cancer and highlights the biggest challenges in both diagnosing and treating this patient population.

October 5th 2019, 3:00pm

Lynn Sage Breast Cancer Symposium

Tari King, MD, FACS, chief of Breast Surgery, Dana-Farber Cancer Institute, Brigham Womens Cancer Center, discusses the role of a multidisciplinary team when considering neoadjuvant chemotherapy (NAC) for patients with breast cancer.

October 5th 2019, 3:05am

Lynn Sage Breast Cancer Symposium

Jonathan B. Strauss, MD, MBA, discussed the role of hypofractionated radiotherapy in patients with breast cancer and offered advice on treatment selection.

October 5th 2019, 2:04am

Lynn Sage Breast Cancer Symposium

As more becomes known about the biology of HER2-positive early breast cancer, C. Kent Osborne, MD, says that a multipronged strategy is the best approach regarding de-escalating chemotherapy in this patient population.

October 5th 2019, 1:54am

Lynn Sage Breast Cancer Symposium

Patricia Ganz, MD, discusses the symptoms related to estrogen hormones that can cause more implications for women with breast cancer, including menopausal symptoms such as hot flashes, vaginal dryness, trouble sleeping, and fatigue.

October 4th 2019, 10:52pm

International Myeloma Society Annual Meeting

Edward A. Stadtmauer, MD, discusses the use of selinexor in patients with heavily pretreated, relapsed/refractory multiple myeloma.

October 4th 2019, 10:46pm

Lynn Sage Breast Cancer Symposium

Clinical guidelines have been necessary to help oncologists stay current in the face of rapidly evolving knowledge in HER2-positive breast cancer.

October 4th 2019, 10:28pm

Lynn Sage Breast Cancer Symposium

Kimberly Van Zee, MD, discusses the importance of preventing invasive recurrence in patients with breast cancer at the 21st Annual Lynn Sage Breast Cancer Symposium.

October 1st 2019, 7:28pm

ESMO Congress

The combination of nivolumab and ipilimumab appears to have durable clinical activity in patients with recurrent or metastatic cervical cancer.

October 1st 2019, 1:56am

ESMO Congress

Men who received cabazitaxel (Jevtana) as a third-line systemic agent for metastatic castration-resistant prostate cancer had a significant reduction in radiographic disease progression, leading to a significant increase in overall survival.

October 1st 2019, 12:40am

ESMO Congress

Nivolumab extended overall survival compared with chemotherapy in patients with previously treated advanced esophageal squamous cell carcinoma.

September 30th 2019, 9:40pm

ESMO Congress

Pembrolizumab (Keytruda) did not show an improvement in progression-free survival compared with chemotherapy in patients with malignant pleural mesothelioma.

September 30th 2019, 6:42pm

ESMO Congress

A population of predominantly Chinese women with advanced hormone receptor–positive/HER2-negative breast cancer obtained significant benefits from treatment with the CDK4/6 inhibitor abemaciclib and endocrine therapy.

September 30th 2019, 6:34pm

ESMO Congress

The first-line combination of atezolizumab (Tecentriq) and chemotherapy led to an improvement in median progression-free survival compared with placebo/chemotherapy in patients with locally advanced or metastatic urothelial carcinoma.

September 30th 2019, 6:30pm

ESMO Congress

Treatment with ivosidenib reduced the risk of progression or death by 63% compared with placebo for pretreated patients with IDH1-mutant advanced cholangiocarcinoma.

September 30th 2019, 6:30pm

ESMO Congress

Olaparib improved radiographic progression-free survival compared with physician's choice of abiraterone acetate or enzalutamide in men with heavily pretreated metastatic castration-resistant prostate cancer with homologous recombination repair (HRR) gene alterations.

September 29th 2019, 10:05pm

ESMO Congress

The tumor-agnostic TRK inhibitor larotrectinib (Vitrakvi) demonstrated marked antitumor efficacy, including objective responses that often persisted for years, and a favorable safety profile.

September 29th 2019, 9:45pm

ESMO Congress

Dennis J. Slamon, MD, PhD, director, Clinical/Translational Research, Revlon/University of California, Los Angeles (UCLA) Women's Cancer Research Program, Jonsson Comprehensive Cancer Center, UCLA, discusses the overall survival results of the phase III MONALEESA-3 trial in hormone receptor-positive, HER2-negative breast cancer.

September 29th 2019, 9:45pm

ESMO Congress

Antonio Gonzalez-Martin, MD, co-director, Department of Medical Oncology, Clinica Universidad de Navarra, discusses the results of the phase III PRIMA trial in advanced ovarian cancer.